Polyoxazoline: chemistry, properties, and applications in drug delivery.

Polyoxazoline polymers with methyl (PMOZ), ethyl (PEOZ), and propyl (PPOZ) side chains were prepared by the living cationic polymerization method and purified by ion-exchange chromatography. The following properties of polyoxazoline (POZ) were measured: apparent hydrodynamic radius by aqueous size-exclusion chromatography, relative lipophilicity by reverse-phase chromatography, and viscosity by cone-plate viscometry. The PEOZ polymers of different molecular weights were first functionalized and then conjugated to model biomolecules such as bovine serum albumin, catalase, ribonuclease, uricase, and insulin. The conjugates of catalase, uricase, and ribonuclease were tested for in vitro activity using substrate-specific reaction methods. The conjugates of insulin were tested for glucose lowering activity by injection to naïve Sprague-Dawley rats. The conjugates of BSA were injected into New Zealand white rabbits and serum samples were collected periodically and tested for antibodies to BSA. The safety of POZ was also determined by acute and chronic dosing to rats. The results showed that linear polymers of POZ with molecular weights of 1 to 40 kDa can easily be made with polydispersity values below 1.10. Chromatography results showed that PMOZ and PEOZ have a hydrodynamic volume slightly lower than PEG; PEOZ is more lipophilic than PMOZ and PEG; and PEOZ is significantly less viscous than PEG especially at the higher molecular weights. When PEOZ was attached to the enzymes catalase, ribonuclease, and uricase, the in vitro activity of the resultant bioconjugates depended on the extent of protein modification. POZ conjugates of insulin lowered blood glucose levels for a period of 8 h when compared to 2 h for insulin alone. PEOZ, like PEG, was also able to successfully attenuate the immunogenic properties of BSA. The POZ polymers (10 and 20 kDa) are safe when administered intravenously to rats, and the maximum tolerated dose (MTD) was greater than 2 g/kg. Blood counts, serum chemistry, organ weights, and the histopathology of key organs were normal. These results conclude that POZ has the desired drug delivery properties for a new biopolymer.

Solubilization of enzymes in water-in-oil microemulsions and their rapid and efficient release through use of a pH-degradable surfactant.

alpha-Chymotrypsin and lysozyme were solubilized in a water/O-[(2-tridecyl, 2-ethyl-1,3-dioxolan-4-yl)methoxy]-O'-methoxy poly(ethylene glycol) (CK-2,13 surfactant)/isooctane water-in-oil microemulsion solution at 1.5-2 and 10 g l(-1) for 0.15 and 1.2 M: CK-2,13, respectively. Upon contact with an equal volume of 0.1 M: NaH(2)PO(4)/Na(2)HPO(4) buffer, pH 5, a three-phase system (Winsor-III system) was formed, consisting of a surfactant-rich middle phase and aqueous and isooctane-rich "excess" phases. Both enzymes were rapidly released into the aqueous excess phase, with 70% recovery of each in 30 and 60 min for microemulsion solutions containing 0.15 and 1.2 M: surfactant, respectively. The recovered enzymes retained >90% of their original specific activity.

A solvolysis model for 2-chloro-2-methyladamantane based on the linear solvation energy approach.

Solvolysis/dehydrohalogenation rates of 2-chloro-2-methyladamantane (CMA) in 15 hydrogen-bond acidic and/or basic solvents are studied. The rates of reaction in these solvents have been correlated with the solvation equation developed by Kamlet, Abraham, and Taft. The linear solvation energy relationship (LSER) derived from this study is given by the following equation: log k = -5.409 + 2.219 + 2.505alpha(1) - 1.823beta(1) where , alpha(1), and beta(1) are the solvation parameters that measure the solvent dipolarity/polarizability, hydrogen-bond acidity (electrophilicity), and hydrogen-bond basicity (nucleophilicity). A high correlation coefficient (r = 0.996, SD = 0.191) was achieved. The cavity term, which includes the Hildebrand parameter for solvent cohesive energy density, delta(H), was not found to be statistically significant for this reaction substrate. The resulting equation allows calculated rates of reaction in other solvents and provides insight into the reaction pathway. In a previously reported correlation for another tertiary chloride, tert-butyl chloride (TBC), the coefficients for alpha(1) and are significantly larger and the coefficient for is statistically significant. In addition, the coefficient for beta(1) in the TBC correlation is positive, rather than negative, indicating that the transition states for TBC and CMA are significantly different. These results demonstrate why the uses of simple solvolytic correlation methods may be invalid even for comparisons of similar type substrates, e.g., tertiary chlorides. Also, these results provide confidence in the use of multiple linear regression analysis for predicting solvolytic rates in additional solvents.

Effect of pegylation on pharmaceuticals.

Protein and peptide drugs hold great promise as therapeutic agents. However, many are degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate neutralizing antibodies and have a short circulating half-life. Pegylation, the process by which polyethylene glycol chains are attached to protein and peptide drugs, can overcome these and other shortcomings. By increasing the molecular mass of proteins and peptides and shielding them from proteolytic enzymes, pegylation improves pharmacokinetics. This article will review how PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance.